Since then, another phase 3 trial has shown that a five-day treatment course with remdesivir on top of standard care was more effective than standard care alone in moderately-ill patients, although strangely a 10-day course wasn't any better.
It is a drug whose first batch will be supplied to Delhi, Maharastra, Gujrat etc.
Remdesivir was reviewed in record time by the CHMP under its rolling review procedure, which allows data on a drug to be reviewed as it becomes available.
AFP reports that at least two major United States studies have shown that remdesivir can reduce the duration of hospital stays for COVID-19 patients.
The company is working closely with the government and medical community to make "Covifor" quickly accessible to both public and private healthcare settings across the country, he added.
Odisha may get its first consignment of remdesivir (brand name Covifor) and favipiravir (brand name FabiFlu), the two drugs approved for Covid-19 treatment in India, within the next four days.
Now, domestic pharmaceutical giant Hetero has begun to provide 20,000 bottles of Covifor (Remdesivir) generic drugs nationwide. Hetero supplied its first batch of the vials to states such as Maharashtra, Delhi, Gujarat, Tamil Nadu and Telengana.
A Hetero spokesperson said that another batch will be provided to Indore, Kolkata, Lucknow, Bhopal, Patna, Bhubaneswar, Vijayawada, Ranchi, Cochin, Trivandrum and Goa to meet emergencies.
A drug originally developed to treat Ebola is now set to be used for treating COVID-19 patients in the EU, after receiving the green light from the European Medicines Agency (EMA). The Ministry of Health documents stated that patients should also not have liver disease and kidney complications.
The product was launched under a licensing agreement with Gilead Sciences Inc.The goal is to expand access to COVID-19 treatment in low- and middle-income countries.
European Medicines Agency (EMA) recommended on Thursday granting a conditional marketing authorization (CMA) to Gilead's antiviral drug called remdesivir, for the treatment of COVID-19 in adults and adolescents from 12 years of age with pneumonia who require supplemental oxygen.
It said its assessment was based mainly based on data from a study sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID).